Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Up 4,233.3% in October

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 65,000 shares, an increase of 4,233.3% from the October 15th total of 1,500 shares. Based on an average trading volume of 351,700 shares, the days-to-cover ratio is presently 0.2 days. Approximately 4.6% of the company’s shares are sold short.

Salarius Pharmaceuticals Price Performance

Shares of NASDAQ:SLRX traded down $0.04 during trading on Tuesday, reaching $1.46. 20,546 shares of the company were exchanged, compared to its average volume of 796,429. The firm has a market capitalization of $2.10 million, a PE ratio of -0.12 and a beta of 0.93. The business’s fifty day simple moving average is $1.57 and its 200-day simple moving average is $2.41. Salarius Pharmaceuticals has a 12-month low of $1.26 and a 12-month high of $7.27.

Salarius Pharmaceuticals (NASDAQ:SLRX) last issued its earnings results on Friday, August 9th. The company reported ($2.37) EPS for the quarter, topping analysts’ consensus estimates of ($53.60) by $51.23.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.